Clinical trials: Acarbose
Tolerance, Side Effect
The Efficacy and Tolerability of Acarbose in Healthy Individuals
A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.
- Conditions
- Tolerance, Side Effect, Glucose Response
- Trial name
- NCT05542849
- Testing
- Acarbose Tablets 50mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Type 2 Diabetes
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
This study is aimed to investigate the effect of acarbose on intestinal microbiome and incretins, therefore to explore the new pathways or new targets to treat type 2 diabetes.
- Trial name
- NCT01758471
- Testing
- Glipizide, Acarbose
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diabetes Mellitus, Type II
Bioequivalence Study for Acarbose / Metformin FDC
To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).
- Trial name
- NCT01728740
- Testing
- Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Aging
Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)
This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans.
- Trial name
- NCT02865499
- Testing
- acarbose
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet
To establish the bioequivalence between Glucobay ODT (Orally Disintegrating Tablet) taken without or with water and the Glucobay standard tablet taken with water
- Trial name
- NCT01388153
- Testing
- Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay, BAYG5421)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Pediatric Obesity, Insulin Resistance
Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity
The main purpose of this study is to determine whether treatment with acarbose attenuates post-prandial glycemic excursions in non-diabetic/pre-diabetic obese children as determined by continuous glucose monitoring systems…
- Conditions
- Pediatric Obesity, Insulin Resistance, Impaired Glucose Tolerance, Cardiovascular Disease
- Trial name
- NCT00846521
- Testing
- Acarbose
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Yale University
Diabetes Mellitus, Type 2
Bioequivalence Study for Acarbose/Metformin FDC
The purpose of this study is to establish the bioequivalence (i.e. similar pharmacokinetics and pharmacodynamics characteristics) between acarbose/metformin FDC (50 mg/500 mg) and loose combination of acarbose (50 mg) and…
- Trial name
- NCT04065581
- Testing
- Acarbose/Metformin FDC(BAY81-9783), Glucobay, Glucophage
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Aging
Study of Acarbose in Longevity
The investigators are studying the effects of acarbose on muscle and adipose gene transcription in older adults.
- Trial name
- SAIL (NCT02953093)
- Testing
- Acarbose
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Diabetes Mellitus, Type 2
A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg
To establish the bioequivalence between Glucobay ODT (Orally Disintegrating Tablet) 100 mg taken without or with water and the Glucobay standard tablet 100 mg taken with water.
- Trial name
- NCT01554631
- Testing
- Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay, BAYG5421)
- Where
- Germany
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers
The objectives were to investigate the relative bioavailability of BI 44847 in different racial groups (white, Asian, and African subjects) and to investigate the effect of different types of diet and acarbose coadministration on…
- Trial name
- NCT02211950
- Testing
- BI 44847, Acarbose, Japanese diet
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim